Stéphane Champiat
@champiatMD
Followers
841
Following
44
Media
20
Statuses
238
Medical Oncologist / Immune Believer @gustaveroussy #DITEP
Joined October 2016
We had an informal welcoming for @champiatMD with Dr. Tim Yap today with Texas BBQ and Texas Boots! Welcome to @MDAndersonNews and to Texas, Dr Champiat!
1
2
30
💻 Plus que 7 jours avant le symposium Itox de @GustaveRoussy et @Hopital_Bicetre dédié aux effets indésirables induits par les #immunothérapies en #cancérologie Pour préparer cet événement et revoir les discussions de l'an dernier : https://t.co/eahunnvrZZ
0
1
1
Met with @champiatMD who showed me around this incredible facility and gave me a signed copy of his book (in French)! Met #AurelienMarabelle, @BenjaminBesseMD, and many other leading figures! Hope to visit again soon!!
0
2
8
Sex matters in immunotherapy ! Impact of sex on response to ICI & occurrence of some IRAE. Potential immunosuppressive impact of Androgens. Could androgen dosing in clinics help identify patients at risk of IRAE / correlate to response? #ESMOImmuno23 @champiatMD @prochigneux
1
5
24
« À l’ère de la personnalisation des traitements en oncologie à partir des profils mutation des tumeurs, l’arrivée de vaccins personnalisés en cancérologie est l’avenir » Dr @champiatMD @GustaveRoussy
#Big2023
0
1
5
Very excited about working with @Veracyte to implement multi-omics immune profiling @GustaveRoussy to enhance the development of next-generation immunotherapies and pave the way for personalized immunotherapy, with the ultimate aim of improving patient benefits!
Veracyte and @GustaveRoussy, a world-leading cancer center, are combining their respective capabilities to provide new insights into the underlying biology of metastatic tumors that may help biopharmaceutical companies accelerate the development of new #cancertherapies.
0
0
9
Veracyte and @GustaveRoussy, a world-leading cancer center, are combining their respective capabilities to provide new insights into the underlying biology of metastatic tumors that may help biopharmaceutical companies accelerate the development of new #cancertherapies.
0
6
4
📢 C'est officiel, la formation Toxicités des Immunothérapies @AFCOR_ est publiée Action DPC @ThierryAndr @CharlotteDomblides @SChampiat @AuroreVozy @YannVANO @ThomasSAMAILLE @RomainCOHEN @SylvieNEGRIER vous attendent le vendredi 06 octobre 2023 https://t.co/YZC93Vfswe
0
3
3
New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology https://t.co/ZEXLoyAfRc
@DrJNaidoo @JulieBrahmer @EladSharonMD @cappelliMD
2
53
127
A subset of pts experiences paradoxical rapid cancer progression during #immunotherapy (hyperprogressive disease (HPD)). A triple-high (IFNγ/FGF/β-catenin) gene signature is associated with HPD. This may serve as a surrogate marker for HPD https://t.co/YMsgPcST7k
0
35
88
Hyperprogression Explained ? —> Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy @champiatMD @jsoriamd #Bed2Bench
cell.com
Li et al. uncover crosstalk between core immunogenic, metabolic, and oncogenic pathways in cancer cells during immunotherapy, which enables hyperprogressive disease (HPD) in preclinical models and...
0
9
22
🚨Pr Marabelle @GustaveRoussy lance l’émission Highlights 2022 en immuno-oncologie de la société française d’immunothérapie des cancer @FITC_cancer #immunotherapie #cancer rejoignez-nous !
1
13
35
#GustaveRoussy dans le top 3 mondial du classement @Newsweek 2023 des hôpitaux en #cancérologie ! Ce classement vient saluer notre engagement en termes de recherche clinique et d’innovations pour améliorer la vie des #patients touchés par un #cancer
https://t.co/Q6zST1VCaQ
2
37
117
Symposium iTOX 2022 à la @ciup_fr ! Identifier et comprendre les toxicités des immunothérapies anti tumorales @GustaveRoussy #immunotherapy #toxicities #irAE #CancerImmunotherapy
0
5
16
C'est parti pour la 5ème édition du symposium ITOX sur les #toxicités des #immunothérapies dans le #cancer
#ITOX22 ▶️ https://t.co/roCVhsOSWn
0
4
6
High-risk non muscle-invasive bladder cancer is treated by resection & BCG therapy. Half of such patients can relapse. This paper demonstrates that BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. https://t.co/VlUvakWFCE
0
13
38
Proud to present @AACR #AACR2022 the promising results of @SOTIO SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembro @GustaveRoussy
1
11
23
0
3
7
0
7
35
Last day of my big big friend @drcmassard at @GustaveRoussy, One of the kindest people you can meet, he did so much for Gustave Roussy, teams and patients here !
5
10
72